Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i> -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531 - Concepedia

Concepedia

Publication | Open Access

Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i> -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531

DOI Full Paper Access

105

Citations

32

References

2021

Year

Jessica A. Pollard, Erin Guest, Todd A. Alonzo, Robert B. Gerbing, Mike R. Loken, Lisa Eidenschink Brodersen, E. Anders Kolb, Richard Aplenc, Soheil Meshinchi, Susana C. Raimondi,

Journal of Clinical Oncology

Abstract

GO added to conventional chemotherapy improved outcomes for <i>KMT2A</i>-r AML; consolidation with HSCT may further enhance outcomes. Future clinical trials should study CD33-targeted agents in combination with HSCT for pediatric <i>KMT2A-</i>r AML.

References

	Year	Citations

Page 1